References
- Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387:1109–1122.
- Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014;69(1):3–16.
- Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284–1293.
- Pugliarello S, Cozzi A, Gisondi P, et al. Phenotypes of atopic dermatitis. J Dtsch Dermatol Ges. 2011;9:12–20.
- [No authors listed]. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1):23–31.
- Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group Exp Dermatol. 2001;10(1):11–18.
- Leshem YA, Hajar T, Hanifin JM, et al. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353–1357.
- Futamura M, Leshem YA, Thomas KS, et al. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol. 2016;74(2):288–294.
- Van Leent EJ, Gräber M, Thurston M, et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol. 1998;134(7):805–809.
- Hanifin JM. Standardized grading of subjects for clinical research studies in atopic dermatitis: workshop report. Acta Derm Venereol Suppl (Stockh). 1989;144:28–30.
- Brunner PM, Leung DYM, Guttman-Yassky E. Immunologic, microbial, and epithelial interactions in atopic dermatitis. Ann Allergy Asthma Immunol. 2018;120(1):34–41.
- Werfel T, Allam JP, Biedermann T, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336–349.
- Guttman-Yassky E, Suárez-Fariñas M, Chiricozzi A, et al. Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol. 2009;124(6):1235–1244.e58.
- Otsuka A, Nomura T, Rerknimitr P, et al. The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis. Immunol Rev. 2017;278(1):246–262.
- Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65–S76.
- D’Erme AM, Romanelli M, Chiricozzi A. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy. Drug Des Devel Ther. 2017;11:1473–1480.
- Suárez-Fariñas M, Tintle SJ, Shemer A, et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol. 2011;127(4):954–64.e1-4.
- Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139(6):1723–1734.
- Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012;67(12):1475–1482.
- Tokura Y. Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Sci. 2010;58(1):1–7.
- Noda S, Suarez-Farinas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136(5):1254–1264.
- Suarez-Farinas M, Dhingra N, Gittler J, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013;132(2):361–370.
- Esaki H, Brunner PM, Renert-Yuval Y, et al. Early onset pediatric atopic dermatitis is Th2, but also Th17 polarized in skin. J Allergy Clin Immunol. 2016;138(6):1639–1651.
- Katsunuma T, Kawahara H, Yuki K, et al. Impaired interferon-gamma production in a subset population of severe atopic dermatitis. Int Arch Allergy Immunol. 2004;134(3):240–247.
- Czarnowicki T, Esaki H, Gonzalez J, et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets. J Allergy Clin Immunol. 2015;136(4):941–951.e3.
- Czarnowicki T, Gonzalez J, Shemer A, et al. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. J Allergy Clin Immunol. 2015;136(1):104–115.e7.
- Czarnowicki T, Esaki H, Gonzalez J, et al. Alterations in B-cell subsets in pediatric patients with early atopic dermatitis. J Allergy Clin Immunol. 2017;140(1):134–144.e9.
- Nakajima S, Kitoh A, Egawa G, et al. IL-17A as an inducer for Th2 immune responses in murine atopic dermatitis models. J Invest Dermatol. 2014;134(8):2122–2130.
- Hanifin JM. Phosphodiesterase and immune dysfunction in atopic dermatitis. J Dermatol Sci. 1990;1(1):1–6.
- Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol. 1996;107(1):51–56.
- Zane LT, Chanda S, Jarnagin K, et al. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. Immunotherapy. 2016;8(8):853–866.
- Tom WL, Van SM, Chanda S, et al. Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis. An open-label Phase 2a study. Pediatr. Dermatol. 2016;33(2):150–159.
- Hanifin JM, Ellis CN, Frieden IJ, et al. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2016;75(2):297–305.
- Stein Gold LF, Spelman L, Spellman MC, et al. A phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis. J Drugs Dermatol. 2015;14(12):1394–1399.
- Ahluwalia J, Udkoff J, Waldman A, et al. Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: progress and Outlook. Drugs. 2017;77(13):1389–1397.
- Draelos ZD, Stein Gold LF, Murrell DF, et al. Post hoc analyses of the effect of crisaborole topical ointment, 2% on atopic dermatitis. associated pruritus from Phase 1 and 2 clinical studies. J. Drugs Dermatol. 2016;15(2):172–176.
- Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494–503.e4.
- Ahmed A, Solman L, Williams HC. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal. Br J Dermatol. 2018;178(3):659–662.
- Furue M, Kadono T, Tsuji G, et al. Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis. Expert Opin Investig Drugs. 2017;26(12):1403–1408.
- Nemoto O, Hayashi N, Kitahara Y, et al. Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: results from a randomized, vehicle-controlled exploratory trial. J Dermatol. 2016;43(8):881–887.
- Esaki H, Ewald H, Ungar B, et al. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. J Allergy Clin Immunol. 2015;135(1):153–163.
- Suárez-Fariñas M, Ungar B, Correa Da Rosa J, et al. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. J. Allergy Clin Immunol. 2015;135:1218–1227.
- Renert-Yuval Y, Guttman-Yassky E. Systemic therapies in atopic dermatitis: the pipeline. Clin Dermatol. 2017;35(4):387–397.
- https://clinicaltrials.gov/ct2/show/NCT03257644
- https://clinicaltrials.gov/ct2/results?term=upadacitinib&cond=atopic+dermatitis&age_v=&age=0&gndr=&type=&rslt=&Search=Apply
- https://clinicaltrials.gov/ct2/results?cond=atopic+dermatitis&term=PF-04965842&cntry=&state=&city=&dist=&Search=Search&age=0
- Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural ahr agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137(10):2110–2119.
- Peppers J, Paller AS, Maeda-Chubachi T, et al. A phase 2, randomized dose-finding study of tapinarof (gsk2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol. 2018. publication ahead to print. DOI:10.1016/j.jaad.2018.06.047.
- https://globenewswire.com/news-release/2015/02/17/706884/10120438/en/Celsus-Therapeutics-Announces-That-the-Phase-II-Trial-of-MRX-6-Cream-2-in-Pediatric-Atopic-Dermatitis-Did-Not-Reach-Primary-Endpoint.html
- Nygaard U, Deleuran M, Vestergaard C. Emerging treatment options in atopic dermatitis: topical therapies. Dermatology. 2017;233(5):333–343.
- https://clinicaltrials.gov/ct2/show/NCT03571620?term=Q301&cond=atopic+dermatitis&age=0&rank=1
- Lim KM, Park YH. Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch Pharm Res. 2012;35(3):393–396.
- https://clinicaltrials.gov/ct2/results?cond=atopic+dermatitis&term=PAC-14028&cntry=&state=&city=&dist=&Search=Search&age=0
- Schmuth M, Elias PM, Hanley K, et al. The effect of LXR activators on AP-1 proteins in keratinocytes. J Invest Dermatol. 2004;123(1):41–48.
- Lee SH, Jeong SK, Ahn SK. An update of the defensive barrier function of skin. Yonsei Med J. 2006;47(3):293–306.
- https://clinicaltrials.gov/ct2/results?cond=atopic+dermatitis&term=ALX-101&cntry=&state=&city=&dist=&Search=Search&age=0
- Abstract #5279: Pharmacokinetics, Safety and Efficacy of Dupilumab in a Pediatric Population with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label Phase 2a Trial. Annual Meeting of the American Academy of Dermatology (AAD) in Orlando, Fla., March 3 – 7, 2017
- http://www.mdedge.com/edermatologynews/article/133798/atopic-dermatitis/dupilumab-improved-eczema-scores-children-open
- https://clinicaltrials.gov/ct2/results?cond=atopic+dermatitis&term=dupilumab&cntry=&state=&city=&dist=&Search=Search&age=0
- https://clinicaltrials.gov/ct2/show/NCT03526861?term=tralokinumab&cond=atopic+dermatitis&age=0&rank=1
- Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol. 2007;7(5):365–378.
- Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003;112(8):1147–1154.
- Lacombe Barrios J, Bégin P, Paradis L, et al. Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective. J Am Acad Dermatol. 2013;69(5):832–834.
- Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol. 2007;120(5):1223–1225.
- Ramírez Del Pozo ME1, Contreras CE, López TJ, et al. Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema. J Investig Allergol Clin Immunol. 2011;21(5):416–417.
- Iyengar SR, Hoyte EG, Loza A, et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol. 2013;162(1):89–93.
- Heil PM, Maurer D, Klein B, et al. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges. 2010;8(12):990–998.
- Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol. 2005;53(2):338–340.
- Vigo PG, Girgis KR, Pfuetze BL, et al. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol. 2006;55(1):168–170.
- Kim DH, Park KY, Kim BJ, et al. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol. 2013;38(5):496–500.
- Zink A, Gensbaur A, Zirbs M, et al. Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab. Acta Derm Venereol. 2016;96(1):72–76.
- Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immunol. 2017;140(3):633–643.
- Chan S, Cornelius V, Chen T, et al. Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT): the role of anti-IgE in severe paediatric eczema: study protocol for a randomised controlled trial. Trials. 2017;18(1):136.
- Dinarello CA, Simon A. van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633–652.
- https://clinicaltrials.gov/ct2/show/NCT01122914
- Wilkes SR, Nankervis H, Tavernier E, et al. More atopic dermatitis trials using standard treatments as active comparators, please. J Invest Dermatol. 2017;137(6):1365–1366.
- Siegfried EC, Jaworski JC, Eichenfield LF, et al. Optimizing clinical trials for atopic dermatitis in children. J Invest Dermatol. 2017;137(6):1363–1364.